Evaluation of the Effectiveness of Intranasal Application of Colloidal Silver Solution Deflu® Silver Nose in the Complex Treatment of Moderate-to-Severe Acute Viral Rhinosinusitis for the Prevention of Bacterial Complications | Ukrainian Medical Journal

Deeva Yu.V.

Main
Publications
Evaluation of the Effectiveness of Intranasal Application of Colloidal Silver Solution Deflu® Silver Nose in the Complex Treatment of Moderate-to-Severe Acute Viral Rhinosinusitis for the Prevention of Bacterial Complications

Evaluation of the Effectiveness of Intranasal Application of Colloidal Silver Solution Deflu® Silver Nose in the Complex Treatment of Moderate-to-Severe Acute Viral Rhinosinusitis for the Prevention of Bacterial Complications

September 9, 2025

1402

Otorhinolaryngology

Deeva Yu.V.

УДК: 616.211-002.1

DOI: 10.32471/umj.1680-3051.268622

Keywords :

acute rhinosinusitis,

colloidal silver,

nanosilver,

prevention of bacterial complications,

SNOT-22,

visual analog scale

Specialities :

Otorhinolaryngology

Resume

Objective: to evaluate the effectiveness of intranasal application of colloidal silver solution Deflu^® Silver Nose in the complex treatment of moderate-to-severe acute viral rhinosinusitis for the prevention of bacterial complications.

Materials and methods. A prospective controlled study was conducted involving 50 patients aged 18–65 years with moderate-to-severe acute viral rhinosinusitis. Patients were evenly divided into two groups: the study group (n=25) received standard treatment with the addition of Deflu^® Silver Nose, while the control group (n=25) received only standard treatment. The observation period was 14 days. Efficacy was assessed using the SNOT-22 scale and a ten-point visual analog scale for nasal symptoms.

Results. On day 7 of treatment, the Deflu^® Silver Nose group showed significantly lower scores for nasal congestion (2.2±0.6 vs. 4.0±0.5, p<0.0001), facial pain/pressure (0.9±0.5 vs. 1.9±0.6, p<0.0001), and olfactory dysfunction (1.9±0.6 vs. 2.9±0.5, p<0.0001) compared to the control group. The total visual analog scale score was statistically lower in the study group (14.1±1.4 vs. 16.1±1.3; p<0.0001), as was the SNOT-22 score (19.4±7.0 vs. 24.5±6.1; p<0.01). The combined efficacy index was 62.3±5.9% vs. 54.6±5.4% (p<0.0001), and the effect stability index was 46.4±6.6% vs. 36.0±7.8% (p<0.0001). No adverse effects or bacterial complications were registered in either group.

Conclusions. Intranasal application of colloidal silver solution Deflu^® Silver Nose in the complex treatment of moderate-to-severe acute viral rhinosinusitis is a safe and effective method for improving clinical symptoms and preventing bacterial complications, allowing its recommendation for inclusion in treatment protocols for this pathology.

References

1. Fokkens W.J., Lund V.J., Hopkins C. et al. (2020) European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology, 58(Suppl. S29): 1–464.
2. Palmer J.N., Messina J.C., Biletch R. et al. (2019) A cross-sectional, population-based survey of U.S. adults with symptoms of chronic rhinosinusitis. Allergy Asthma Proc., 40: 48–56.
3. Orlandi R.R., Kingdom T.T., Smith T.L. et al. (2021) International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int. Forum Allergy Rhinol.,11: 213–739.
4. Tatar E.C., Tingle M., Kim R. et al. (2022) Topical antibiofilm agents with potential utility in the treatment of chronic rhinosinusitis: A narrative review. Front. Pharmacol., 13: 840323.
5. Fokkens W.J., Lund V.J., Mullol J. et al. (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology, 58: 1–464.
6. Chernousova S., Epple M. (2013) Silver as antibacterial agent: ion, nanoparticle, and metal. Angewandte Chemie Int. Ed., 52: 1636–1653.
7. Richter K., Facal P., Thomas N. et al. (2017) Taking the silver bullet colloidal silver particles for the topical treatment of biofilm-related infections. ACS Appl. Mater. Interfaces, 9: 21631–21638.
8. Goggin R., Jardeleza C., Wormald P.J., Vreugde S. (2014) Colloidal silver: a novel treatment for Staphylococcus aureus biofilms? Int. Forum Allergy Rhinol., 4: 171–175.
9. Rajiv S., Drilling A., Bassiouni A. et al. (2015) Topical colloidal silver as an anti-biofilm agent in a Staphylococcus aureus chronic rhinosinusitis sheep model. Int. Forum Allergy Rhinol., 5: 283–288.
10. Richter K., Facal P., Thomas N. et al. (2017) Taking the silver bullet colloidal silver particles for the topical treatment of biofilm-related infections. ACS Appl. Mater Interfaces, 9: 21631–21638.
11. Scott J.R., Krishnan R., Rotenberg B.W., Sowerby L.J. (2017) The effectiveness of topical colloidal silver in recalcitrant chronic rhinosinusitis: a randomized crossover control trial. J. Otolaryngol. Head Neck Surg., 46: 64.
12. Ooi M.L., Richter K., Bennett C. et al. (2018) Topical colloidal silver for the treatment of recalcitrant chronic rhinosinusitis. Front. Microbiol., 9: 720.
13. Falconer J.L., Alt J.A., Grainger D.W. (2018) Comparing ex vivo and in vitro translocation of silver nanoparticles and ions through human nasal epithelium. Biomaterials, 1–34.
14. Zhao X., Zhao C., Zhang X., Xing L. (2020) Benefits of a nanosilver nasal spray for postoperative care of patients with chronic rhinosinusitis. J. Nanosci. Nanotechnol., 20: 7342–7346.
15. Falconer J.L., Grainger D.W. (2018) In vivo comparisons of silver nanoparticle and silver ion transport after intranasal delivery in mice. J. Control. Rel., 269: 1–9.
16. Ottaviano G., Staffieri A., Staffieri C. et al. (2015) Silver sucrose octasulfate nasal applications and wound healing after endoscopic sinus surgery: a prospective, randomized, double-blind, placebo-controlled study. Am. J. Otolaryngol., 36: 625–631.
17. Nadworny P.L., Wang J., Tredget E.E., Burrell R.E. (2010) Anti-inflammatory activity of nanocrystalline silver-derived solutions in porcine contact dermatitis. J. Inflamm. (Lond)., 7: 13.
18. Hyun J.S., Lee B.S., Ryu H.Y. et al. (2008) Effects of repeated silver nanoparticles exposure on the histological structure and mucins of nasal respiratory mucosa in rats. Toxicol. Lett., 182(1–3): 24–28.
19. Nadworny P.L., Hickerson W.L., Holley-Harrison H.D. et al. (2023) Treatment of infection and inflammation associated with COVID-19, multi-drug resistant pneumonia and fungal sinusitis by nebulizing a nanosilver solution. Nanomedicine, 48: 102654.